血友病的新兴疗法:改善公平获得护理的机会
Magdalena Lewandowska1, Sonia Nasr2, Amy D Shapiro1
1Indiana Hemophilia & Thrombosis Center, Inc., Indianapolis, Indiana, USA.
Journal of blood medicine
|February 25, 2025
概括
基因疗法和新型血液静止剂正在改善血友病护理. 然而,实现健康公平需要解决全球所有患者的诊断和治疗障碍.
科学领域:
- 血液学 血液学 血液学
- 基因治疗 基因治疗
- 生物技术是生物技术.
背景情况:
- 基因疗法和生物工程化静血分子已经显著提升了血友病治疗.
- 创新疗法旨在减少治疗负担,提高患者的生活质量.
- 下一代模仿剂和血静再平衡剂正在临床研究中.
研究的目的:
- 为了突出血友病治疗的进步.
- 解决诊断和有效护理的全球差异.
- 强调在血友病管理中需要健康公平.
主要方法:
- 审查当前的基因疗法和生物工程静血分子的进展.
- 分析技术创新,如护理点超声波和血友病护理中的AI.
- 确定最佳护理的障碍,包括社会经济,人口和临床因素.
主要成果:
- 新型疗法提供革命性的治疗潜力,改善生活质量.
- 技术进步可能会提高诊断和治疗结果.
- 全球仍然存在显著的差异,许多患者无法获得诊断和有效治疗.
结论:
- 实现健康公平需要识别和克服与社会经济地位,种族/种族,性别,疾病严重程度,抑制剂状态,年龄和血友病治疗中心利用相关的障碍.
- 确保公平获得新型血友病疗法至关重要.
- 以患者为中心的方法,包括共享决策,利益相关者参与和行业支持,对于利用新疗法来改善健康公平至关重要.
相关概念视频
X-linked Traits
53.0K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
53.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
593
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
593
Disorders of Hemostasis
680
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
680
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Issues And Trends In Healthcare Delivery System
5.6K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
5.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
455
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
455


